EUVIMEDEUVIMED entdecken
Crossref

6‐Mercaptopurine metabolic profiles and clinical outcomes in TPMT and NUDT15 phenotypes during maintenance therapy for Thai paediatric acute lymphoblastic leukaemia

Angkana Winaichatsak, Samart Pakakasama, Usanarat Anurathapan, Piti Techavichit, Hansamon Poparn, Darintr Sosothikul, Lalita Sathitsamitphong, Supaporn Wiwattanakul, Piya Rujkijyanont, Apichaya Puangpetch iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70634 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Angkana Winaichatsak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand. Hauptthemen laut MEDLINE: Mercaptopurine, Pyrophosphatases, Methyltransferases, Antimetabolites, Antineoplastic. Die Arbeit nennt 50 Literaturangaben. Gefördert von: The Health Systems Research Institute under Genomics Thailand Strategic Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study aimed to investigate the real‐world profiles of 6‐mercaptopurine (6‐MP) treatment in various TPMT/NUDT15 phenotype groups among paediatric patients with ALL.

Methods

We conducted a prospective cohort study of 104 paediatric patients with ALL during the maintenance phase, collecting baseline data and following up monthly for 5 months. Patients were genotyped and classified as normal (NM), intermediate (IM) or poor (PM) metabolizers based on the TPMT and NUDT15 genetic variations. Additionally, TPMT activity and metabolite concentrations (6‐thioguanine nucleotides; 6‐TGN and 6‐methylmercaptopurine nucleotides; 6‐MMPN) were also quantified.

Results

The patients were categorized into five TPMT/NUDT15 phenotype groups: NM/NM (73.08%), NM/IM (17.31%), NM/PM (1.92%), IM/NM (3.85%) and IM/IM (3.85%). The tolerated 6‐MP dose was lowest in the NM/PM group (18 mg/m 2 , IQR = 8–29 mg/m 2 ) and IM/IM group (25 mg/m 2 , IQR = 8–26 mg/m 2 ). The IM/IM had the highest rate of early neutropenia (75%). TPMT activity remained stable throughout the study except in the NM/PM group, which showed significant fluctuations. Patients with NM/PM had the lowest 6‐TGN level, and patients with IM/NM showed high 6‐TGN levels. Patients with NM/NM and NM/IM exhibited elevated levels of 6‐MMPN, which were associated with the occurrence of hepatotoxicity.

Conclusion

The TPMT and NUDT15 genes influence the side effects of 6‐MP medications. Patients who have variations in both genes are at a higher risk of experiencing toxicity. High levels of 6‐TGN are associated with TPMT variants, whereas low levels are linked to NUDT15 variants. This could facilitate more precise monitoring of toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MercaptopurinePyrophosphatasesMethyltransferasesAntimetabolites, AntineoplasticPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansNudix HydrolasesChildFemalePhenotypeChild, PreschoolProspective StudiesMaleThailandAdolescentGenotypeTreatment OutcomeInfant

Stichwörter der Autor:innen

6‐MMPN6‐TGN6‐mercaptopurineALLNUDT15TPMT

Substanzen

MercaptopurineNUDT15 protein, humanPyrophosphatasesNudix HydrolasesMethyltransferasesTPMT protein, humanAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Pediatrics, Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand.
  • Division of Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Center of Excellence in Pediatric Hematology/Oncology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Pathology, Faculty of Medicine, Srinakharinwirot University, Nakornnayok, Thailand.

ORCID-Profile: Apichaya Puangpetch

Förderung

  • The Health Systems Research Institute under Genomics Thailand Strategic Fund

Zitieren

APA

Winaichatsak, A., Pakakasama, S., Anurathapan, U., Techavichit, P., Poparn, H., Sosothikul, D., Sathitsamitphong, L., Wiwattanakul, S., Rujkijyanont, P., & Puangpetch, A. (2026). 6‐Mercaptopurine metabolic profiles and clinical outcomes in TPMT and NUDT15 phenotypes during maintenance therapy for Thai paediatric acute lymphoblastic leukaemia. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70634

Vancouver

Winaichatsak A, Pakakasama S, Anurathapan U, Techavichit P, Poparn H, Sosothikul D, et al. 6‐Mercaptopurine metabolic profiles and clinical outcomes in TPMT and NUDT15 phenotypes during maintenance therapy for Thai paediatric acute lymphoblastic leukaemia. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70634

BibTeX
@article{Winaichatsak2026,
  author = {Winaichatsak, Angkana and Pakakasama, Samart and Anurathapan, Usanarat and Techavichit, Piti and Poparn, Hansamon and Sosothikul, Darintr and Sathitsamitphong, Lalita and Wiwattanakul, Supaporn and Rujkijyanont, Piya and Puangpetch, Apichaya},
  title = {6‐Mercaptopurine metabolic profiles and clinical outcomes in TPMT and NUDT15 phenotypes during maintenance therapy for Thai paediatric acute lymphoblastic leukaemia},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70634}
}
Kostenlos starten →